A single course of newly approved Alzheimer's drug donanemab-azbt, the second medicine available in Japan targeting proteins in the brains of sufferers of the debilitating disease, will cost 3.08 ...
Frailty is associated with an increased risk for dementia, new findings showed, with an acceleration of frailty observed 4-9 years prior to dementia onset.